Sign in
CompletedPhase 4

Intraosseous Versus Intravenous Vancomycin in Below-Knee Amputation for Ischemic Diabetic Foot

Key facts

Who runs it
Başakşehir Çam & Sakura City Hospital
Where
Türkiye1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
40 people enrolled
Started
6 Aug 2025
Ended
21 Jun 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Intraosseous Vancomycin
  • Intravenous Vancomycin
Record updated
10 July 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (13)Hide the full registry criteria

Who can take part

  • Age 18 years or older
  • Diagnosis of diabetes mellitus
  • Diabetic foot infection with distal ischemia
  • Scheduled to undergo below-knee amputation
  • Absence of a feasible further revascularization option, as determined by the cardiovascular surgery and interventional radiology teams
  • Adequate circulation at and proximal to the planned below-knee amputation level for stump healing
  • Ability to provide written informed consent

Who cannot take part

  • Systemic vancomycin use within 48 hours before surgery
  • Previous Syme amputation or more proximal amputation
  • Documented allergy or hypersensitivity to vancomycin or cephalosporins
  • Dialysis dependence
  • Planned amputation at a level other than below the knee
  • Incomplete perioperative pharmacokinetic sampling

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This randomized clinical trial compared two routes of vancomycin administration in patients undergoing below-knee amputation for ischemic diabetic foot infection. Patients with diabetic foot infection and impaired lower-extremity circulation may have reduced delivery of intravenously administered antibiotics to the amputation stump. Intraosseous administration may increase local antibiotic exposure at the surgical site while reducing systemic exposure.

Read full original descriptionShow less

Participants were randomly assigned to receive either intraosseous vancomycin or intravenous vancomycin before skin incision. The study evaluated vancomycin concentrations in amputation stump subcutaneous tissue, simultaneous serum vancomycin concentrations, tissue-to-serum concentration ratios, inflammatory marker trajectories, early wound outcomes, pain scores, drain output, reintervention, mortality, renal safety, and systemic adverse events through postoperative follow-up.

The 2 groups in the trial

  • Intraosseous VancomycinTreatment being tested

    Participants received 500 mg of vancomycin diluted in 100 mL of 0.9% normal saline via intraosseous administration into the proximal tibial metaphysis immediately before skin incision.

  • Intravenous VancomycinExisting treatment, for comparison

    Participants received 500 mg of vancomycin intravenously at the same preincision time point before below-knee amputation.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Does Intraosseous Compared With Intravenous Vancomycin Alter Local Exposure, Systemic Safety, and Early Outcomes in Patients With Ischemic Diabetic Foot Undergoing Below-knee Amputation? A Randomized Trial
Record updated
10 July 2026